2 June 2026

Kromek Group plc
("Kromek", the "Company" or the "Group")

Kromek launches new interactive investor hub

to provide shareholders with a more proactive way of communication and enquiry support

Kromek (AIM:KMK), a global detection company focused on the advanced imaging and CBRN detection markets, announces the launch of the Group's interactive investor hub. For both existing and prospective shareholders, the new investor hub brings all Kromek content into a single integrated platform to better inform and engage with investors and other stakeholders, including:

●    Regulatory announcements

●    Reports

●    Presentations

●    Educational material

●    Interviews

●    Link to corporate research

●    All other disclosures required in accordance with AIM Rule 26

The investor hub also provides an interactive online experience allowing Kromek stakeholders to comment on, and ask, the Kromek team questions via a portal that will be monitored and responded to in a timely manner.

How to sign up for the Kromek Group plc investor hub:

1.   Visit https://investors.kromek.com/

2.   Follow the prompts to sign up for an investor hub account

3.   Complete your account profile

Enquiries

Engage with the Kromek management team directly by asking questions, watching video
summaries and seeing what other shareholders have to say. Navigate to our interactive investor
hub here: https://investors.kromek.com/

Subscribe to our news alert service: https://investors.kromek.com/auth/signup

Kromek Group plc

Kromek Group plc is a leading developer of radiation detection and bio-detection technology solutions for the advanced imaging and CBRN detection segments. Headquartered in County Durham, UK, Kromek has manufacturing operations in the UK and US, delivering on the vision of enhancing the quality of life through innovative detection technology solutions.

The advanced imaging segment comprises the medical (including CT and SPECT), security and industrial markets. Kromek provides its OEM customers with detector components, based on its core cadmium zinc telluride (CZT) platform, to enable better detection of diseases such as cancer and Alzheimer's, contamination in industrial manufacture and explosives in aviation settings.

In CBRN detection, the Group provides nuclear radiation detection solutions to the global homeland defence and security market. Kromek's compact, handheld, high-performance radiation detectors, based on advanced scintillation and solid-state readout technology, are primarily used to protect critical infrastructure, events, personnel and urban environments from the threat of 'dirty bombs'.

The Group is also developing bio-security solutions in the CBRN detection segment. These consist of fully automated and autonomous systems to detect a wide range of airborne pathogens.

Kromek is listed on AIM, a market of the London Stock Exchange, under the trading symbol 'KMK'.